Evidence map›Paper›PMID 30621658›Full record

ArticleBMC public health2019

Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.

H Stöver, F Meroueh, A Marco, K Keppler, P Saiz de la Hoya, R Littlewood, N Wright, F Nava, F Alam, S Walcher and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Hepatitis C virus micro-elimination: Where do we stand?World journal of gastroenterology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

H StöverInstitute of Addiction Research, Frankfurt University of Applied Sciences, Frankfurt, Germany. hstoever@fb4.fra-uas.de.
F MerouehHealth Unit, Villeneuve les Maguelone, France.
A MarcoPenitentiary Program, Catalan Health Institute, Barcelona, Spain.
K KepplerJustizvollzug, Berlin, Germany.
P Saiz de la HoyaHealth Services of Fontcalent Penitentiary Centre, Alicante, Spain.
R LittlewoodApplied strategic, London, UK.
N WrightSpectrum Community Health CIC, Wakefield, UK.
F NavaUniversity of Modena and Reggio Emilia, University Hospital Policlinico of Modena, Modena, Italy.
F AlamDivisional Medical Director, Central and North West London NHS Foundation Trust, London, UK.
S WalcherCONCEPT, Addiction Medicine, Munich, Germany.
L SomainiAddiction Treatment Centre, Biella, Italy.
Central and North West London NHS Foundation Trust · GBFederal Ministry of Justice and Consumer Protection · DEFrankfurt University of Applied Sciences · DEInternational Institute for Strategic Studies · GBSpectrum Community Health CIC · GBUniversity of Modena and Reggio Emilia · IT

Funding

Gilead Sciences Europe This work was funded by Gilead Sciences Europe. Gilead had no influence on the development, research or writing of the manuscript
6 · The paper itself

Abstract

backgroundPrisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-acting antiviral products with superior efficacy and safety compared to interferon-based regimens offer HCV cure. Many citizens in Europe have been treated, although few received therapy in prisons.

methodsAnalysis of prisoner HCV treatment need and policy determinants of clinical practice was completed for 5 EU countries. Evidence was collected from national statistical sources and peer-reviewed publications to describe prison populations and HCV prevalence, to map national prison/ HCV health policy or guidance. A consensus of important principles for prisoner HCV care was developed.

resultsData from published sources describing prisoner HCV prevalence is limited. Prisoner population requiring HCV treatment is not known; estimated numbers based on analysis of evidence: England and Wales, 9000, France, 8000, Spain, 6000, Italy, 6000, Germany, 6000. Treatment access: national law defines right to equivalent care in all countries implying access to HCV therapy in prison similar to community; useful prisoner HCV guidance facilitating treatment decisions present in: 4 of 5 national/ regional HCV policy documents, 4 of 5 national prison healthcare policies. Four of five had practical prison HCV clinical guidelines. Despite existence of policy, implementation of guidance, and so HCV treatment, is suboptimal in many locations.

conclusionsPrison is an important location to detect, address and treat HCV infection in people who may be underserved for healthcare and find it difficult to navigate community treatment pathways. This is often related to problems with OUD and resulting social inequity. HCV management in prisons must be improved. Policy and clinical practice guidance must be set to promote treatment, and practical steps to make treatment easy should be followed including education to promote engagement, set-up of optimal screening and work up processes with modern tools to reduce time needed/ achieve efficiency; programs to make it easier to get specialists' input include remote working and nurse-led services.

Indexed as

PrisonersAntiviral AgentsEuropeHealth PolicyHealth Services AccessibilityHepatitis CHumansPractice Guidelines as TopicPrevalencePrisonsAntiviral AgentsHepatitis C virusPolicyPracticePrisonersTreatment

Identifiers

PMID30621658
PMCPMC6323720
OpenAlexW2947905863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.